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ABSTRACT
Background: We have previously shown that an intensified preoperative regimen 
including oxaliplatin plus raltitrexed and 5-fluorouracil/folinic acid (OXATOM/
FUFa) during preoperative pelvic radiotherapy produced promising results in locally 
advanced rectal cancer (LARC). Preclinical evidence suggests that the scheduling of 
bevacizumab may be crucial to optimize its combination with chemo-radiotherapy.
Patients and methods: This non-randomized, non-comparative, phase II study was 
conducted in MRI-defined high-risk LARC. Patients received three biweekly cycles of 
OXATOM/FUFA during RT. Bevacizumab was given 2 weeks before the start of chemo-
radiotherapy, and on the same day of chemotherapy for 3 cycles (concomitant-schedule 
A) or 4 days prior to the first and second cycle of chemotherapy (sequential-schedule 
B). Primary end point was pathological complete tumor regression (TRG1) rate.
results: The accrual for the concomitant-schedule was early terminated 
because the number of TRG1 (2 out of 16 patients) was statistically inconsistent 
with the hypothesis of activity (30%) to be tested. Conversely, the endpoint was 
reached with the sequential-schedule and the final TRG1 rate among 46 enrolled 
patients was 50% (95% CI 35%–65%). Neutropenia was the most common grade 
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≥3 toxicity with both schedules, but it was less pronounced with the sequential 
than concomitant-schedule (30% vs. 44%). Postoperative complications occurred in 
8/15 (53%) and 13/46 (28%) patients in schedule A and B, respectively. At 5 year 
follow-up the probability of PFS and OS was 80% (95%CI, 66%–89%) and 85% 
(95%CI, 69%–93%), respectively, for the sequential-schedule.
Conclusions: These results highlights the relevance of bevacizumab scheduling to 
optimize its combination with preoperative chemo-radiotherapy in the management 
of LarC.
INTRODUCTION
The evolution of preoperative multimodality 
treatment has improved the local control of locally 
advanced rectal cancer (LARC). Distant metastases, 
however, remain a clinical challenge and more effective 
systemic approaches are needed [1]. LARC comprises a 
heterogeneous group of tumors in which outcomes vary 
significantly depending on prognostic factors, namely T 
and N stage, involvement of the circumferential resection 
margin (CRM) and low-lying location [2]. The high-
resolution magnetic resonance imaging (MRI) allows 
the preoperative identification of high-risk features, 
enabling patient selection for risk-adapted treatment 
[2]. In such high-risk LARC patients we have recently 
reported promising results from a phase-2 trial based 
on an original intensified preoperative chemotherapy 
(CT) regimen including oxaliplatin plus raltitrexed and 
5-fluorouracil modulated by folinic acid (OXATOM/
FUFA) at full systemic doses, during preoperative pelvic 
radiotherapy (RT). High rates of complete (40%) and 
near-complete (25%) pathologic tumor regression were 
observed, with a 5-year freedom from recurrence of 
80% and a 5-year overall survival (OS) of 87% [3]. On 
the basis of preclinical and clinical data the integration 
of bevacizumab into fluoropyrimidines-based chemo-
radiotherapy (CRT) has been extensively investigated 
in phase II studies [4, 5]. However, results overall have 
been modest and concerns regarding increased surgical 
morbidity have been raised [6]. Several evidences suggest 
that the chemo-sensitizing activity exerted by anti-VEGF 
agents depends on the so-called “vessel to normalization, 
in which a reduction of tumor vessel abnormalities results 
in more efficient delivery of drugs and oxygen to cancer 
cells [7]. Although genetic studies have shown prolonged 
maintenance of vascular normalization [8], in preclinical 
models pharmacological VEGF inhibitors induced a 
transient vessel normalization, occurring a few days after 
anti-VEGF administration [9, 10]. Therefore, rescheduling 
of bevacizumab relative to CT and RT could be of critical 
importance to optimize the efficacy of the combination 
treatment. On these basis we conducted a phase-2 study in 
MRI-defined high-risk LARC patients, in order to evaluate 
the addition of bevacizumab to OXATOM/FUFA during 
preoperative RT.
A concomitant schedule, in which bevacizumab was 
administered concurrentlyy to CT, was initially evaluated. 
Thereafter, a sequential schedule, in which bevacizumab 
was given 4 days before CT, was also evaluated in order 
to explore the clinical relevance of “vessel normalization”.
The primary endpoint of the study was the rate of 
TRG1. However, considering the controversial prognostic 
value of short term pathological end points and the paucity 
of data on long-term outcomes of LARC patients, we also 
report on these findings with a prolonged follow-up.
RESULTS
Patient characteristics and treatment
Between December 2006 and July 2011 16 patients 
were enrolled in schedule A (concomitant) and 46 in 
schedule B (sequential). Demographic and baseline 
disease characteristics by treatment schedule are shown 
in Table 1. Most patients had more than one high-risk 
factor. Among patients with radial margin ≤5 mm from 
the mesorectal fascia (MRF), evaluated by MRI and 
considered to have potentially positive CRM, 4/13 (31%) 
in schedule A and 29/35 (83%) in schedule B showed 
tumor location within 2 mm of the MRF. All T3N0-1 
tumors had a potentially positive CRM and/or extramural 
extension ≥5 mm.
All patients in schedule A and all but 1 patient 
in schedule B received the planned dose of RT. The 
radiation treatment was completed in a median of 39 
(range, 35–45) and 36 (range, 33–49) days in schedule 
A and B, respectively. One patient in each group did not 
receive the third cycle of chemotherapy due to severe and 
persistent neutropenia and diarrhea. Overall, the median 
relative dose intensities of cytotoxic drugs were: 87% 
and 97% for oxaliplatin, 87% and 97% for raltitrexed, 
83% and 92% for 5-FU, 94% and 100% for bevacizumab, 
in schedule A and B, respectively. The only patient with 
metastatic disease enrolled in schedule A and 4 out of 7 
metastatic patients in schedule B received two additional 
cycles of chemotherapy after the end of RT. One patient 
in schedule A with a complete clinical response refused 
surgery. The median interval between the end of RT and 
TME was 9 weeks for both schedule A (range, 7–14) and 
B (range, 7–15).
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Outcome
Surgical outcome and pathological tumor responses 
are summarized in Table 2. Notably, the incomplete 
resection in schedule B pertained only to metastatic 
disease. There were no instances of disease progression 
during treatment.
According to the preplanned first-stage analysis, the 
accrual for schedule A was terminated since only 2 TRG1 
responses were identified. Conversely, in schedule B, 8/15 
patients showed a TRG1 in the first stage and 23/46 (50%; 
95% CI, 35%–65%) in the second stage. Importantly, TRG1 
status was achieved independently of the pre-treatment 
clinical stage (Table 3). In addition, 15 patients (33%; 95% 
CI, 21%–47%) obtained a near complete tumor regression 
with schedule B (TRG2, Table 2). Pathological tumor 
downstaging occurred in 39/46 (85%) patients (Table 3).
A median of 32 (range, 19–62) and 27 (range, 12–108) 
lymph nodes per patient were harvested in schedule A and 
B, respectively. Pathological nodal downstaging occurred 
in 32/43 (74%) patients (Table 3). In schedule B, 4 patients 
with TRG1 (2 with baseline metastatic disease) revealed 
pathological nodal involvement. Overall pCR rate was 41% 
and 30/46 (65%) patients had a ypT0–2N0 status (Table 2).
As provided by the selective adjuvant policy 
adopted in the study, 5 patients in schedule A and 13/16 
patients in schedule B (3 patients with baseline metastatic 
disease and R0/R1 resection refused further treatment), 
received post-operative FOLFOX4 after a median of 7 
weeks (schedule A, range: 7–9; schedule B, range: 4–15) 
from surgery. In schedule A, with a median follow-up 
at the time of analysis of 91 (range, 84–96) months, 2 
patients had distant recurrence, 3 patients had both local 
and distant recurrence and 5 patients died.
Table 1: Baseline patient and tumor characteristics
Characteristics Schedule A 
n = 16 (% of total)
Schedule B 
n = 46 (% of total)
Gender
 Male/Female 9 (56)/7 (44) 28 (61)/18 (39)
Median age (range) 55 (48–69) 61 (43–74)
ECOG Performance status
 0 8 (50) 22 (48)
 1/2 7 (44)/ 1 (6) 13 (50)/1 (2)
Clinical staging
 T3N0 3 (19) 1 (2)
 T3N1/T4N0 7 (44)/1 (6) 14 (30)/1 (2)
 T3N2/T4N1-2 2 (12)/2 (12) 22 (48)/1 (2)
 T3N0M1/T3N1M1 − 1 (2)/2 (4)
 T3N2M1/T4N2M1 1 (6)/0 3 (7)/1 (2)
Distance from the anal verge
 ≤5 cm (low-lying tumor) 9 (56) 25 (54)
 >5 cm (mid/upper tumor) 7 (44) 21 (46)
Distance of Mesorectal Fascia (MRF)
 ≤5 mm 13 (81) 35 (76)
 >5 mm 2 (12) 8 (18)
 Not evaluated* 1 (6) 3 (7)
Baseline CEA serum level
 ≤5 UI/L 10 (62) 28(61)
 >5 UI/L 6 (37) 18 (39)
*MRI not performed, metal prosthesis.
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In schedule B after a median follow up of 54 (range, 
41–83) months, 37/46 (80%) patients continued to be 
disease-free. One patient (ypN+) had a local recurrence, 
3 patients (including 1 with early interruption of CRT 
and 1 ypN+) had both local and distant recurrences and 
2 patients (both ypN+) had distant recurrence. Of note, 
4 patients with baseline metastatic disease (3 achieving a 
TRG1 response) were still disease-free. Six patients died 
of rectal cancer specific causes. At 5-years follow-up the 
probability of Progression-free survival (PFS) and OS was 
80% (95%CI, 66%-89%) and, 85% (95%CI, 69%-93%), 
respectively, for schedule B (Figure 1).
Safety
Treatment induced side effects are summarized 
in Table 4. Toxicity profiles were similar between the 
two schedules and neutropenia was the most common 
grade ≥3 adverse event, but it was short lasting and 
easily managed. Notably, severe neutropenia was less 
pronounced in schedule B (30% vs. 44%). Furthermore, 
6/14 (43%) episodes of severe neutropenia in schedule 
B, as opposed to 1/7 (14%) in schedule A, occurred only 
after the end of CRT, thus not causing treatment delays or 
dose modifications. No cardiac or thromboembolic events, 
hemorrhages or perforations were observed.
Postoperative complications occurred in 8/15 (53%) 
and 13/46 (28%) patients in schedule A and B, respectively 
(Table 5). Re-operation was necessary in 3 patients (19%) 
in schedule A and in 4 patients (9%) in schedule B. One 
patient per schedule required a permanent colostomy. 
There were no deaths correlated with CRT or surgery in 
either treatment schedules.
Moderate or severe late toxicities were reported in 
6/15 (40%) and 19/46 (41%) patients in schedule A and B, 
respectively (Table 5).
DISCUSSION
The present results support the hypothesis that 
rescheduling of anti-VEGF treatment relative to CT and 
RT could be of critical importance to improve the efficacy 
of combination treatment. The concomitant delivery of 
Table 2: Surgical outcomes and pathological tumor response
Parameters Schedule A° (n = 16) 
n (%; 95% CI)
Schedule B (n = 46) 
n (%; 95% CI)
Surgery type
 Anterior resection 13 (81;57–93) 41 (89;77–95)
 Abdominoperineal resection 2 (12;3–36) 5 (11;5–23)
 Sphincter preservation in patients 
with tumor ≤5 cm from anal verge
5/9 (56;27–81) 20/25 (80;61–91)
Resection Status
 Complete resection (R0) 13 (81;57–93) 43 (93;82–98)
 Microscopic residual disease (R1) 1* (6;1–28) 1** (2;0–11)
 Macroscopic residual disease (R2) 1* (6;1–28) 2** (4;1–14)
ypTypN status
 ypT0ypN0 (pCR) 2 (12;3–36) 19 (41;28–56)
 ypT0-2ypN0 8 (50;28–72) 30 (65;51–77)
 ypN1-2 5 (31;14–56) 14 (30;19–45)
Mandard tumor regression grade
 TRG1 2 (12;3–36) 23 (50;36–64)
 TRG2 8 (50;28–72) 15 (33;21–47)
 TRG3 3 (19;7–43) 7 (15;7–28)
 TRG4 2 (12;3–36) 1 (2;0–11)
 TRG5 0 0
°one patient refused surgery;
*R1 or R2 resection on primary tumor;
**R1 or R2 resection on metastatic disease
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bevacizumab with the OXATOM/FUFA regimen during 
RT did not meet the primary endpoint.
With the sequential schedule, on the other hand, 
the endpoint was reached in both stages of Simon’s 
statistical design and the final TRG1 rate was 50% (95% 
CI, 35%–65%), slightly better compared to our previous 
experience with the same regimen without bevacizumab 
(40%) [3]. In addition, a near complete tumor regression 
was observed in 15 further patients, with an overall rate 
of TRG1/TRG2 responses of 83% (95% CI, 69%–91%), 
which was higher compared to our previous experience 
without bevacizumab (65%) [3]. Moreover, we should 
also point out that most patients enrolled in the current 
study had more than one high-risk factor, including 15% 
of patients with metastatic disease, who were not included 
in our previous experience.
Although four patients with TRG1 had pathological 
nodal involvement, the 41% pCR rate is still impressive. 
Notably, these results were observed regardless of 
pretreatment clinical stage and were reported through a 
robust pathological analysis, as proven by the elevated 
median number of lymph nodes retrieved. Additional 
remarkable findings were the 93% R0 resection rate, the 
65% ypT0-2N0 rate, the 80% sphincter-sparing surgery 
rate and the clinical or pathological complete response 
of metastatic sites in 3/7 patients. All this data endorses 
the efficacy of the sequential bevacizumab schedule with 
OXATOM/FUFA during RT. The consistency of these 
findings was corroborated by the long-term outcome of 
patients.
Indeed, the 80% 5-year PFS and 85% 5-year OS 
indicates a good and durable distant control. These results 
are particularly relevant considering the poor prognostic 
features of the enrolled patients.
The selective adjuvant policy adopted in our trial 
strengthens the value of these findings, minimizing the 
influence of the adjuvant therapy on long-term outcome. 
Indeed, postoperative FOLFOX4 was delivered only in a 
small subgroup of patients. Although there is no general 
agreement on the benefit of adjuvant chemotherapy 
after preoperative CRT [11], there is recent compelling 
evidence supporting the use of a risk-adapted strategy 
based on pathological findings to select candidates for 
CT after surgery [12, 13]. Moreover, recent results of the 
randomized phase-2 ADORE study in LARC patients 
suggest that those less responsive to fluoropyrimidine-
based CRT may benefit from four months of adjuvant 
FOLFOX chemotherapy [14].
Table 3: Comparison of baseline staging with pathological findings in schedule B
Tumor Regression Grade (TRG)
Schedule B n = 46
TRG1 TRG2 TRG3 TRG4
Baseline Staging n = 23 n = 15 n = 7 n = 1
cT3N0
n = 1 1(ypT2N0)
cT3N1
n = 14
6(ypT0N0);
1(ypT0N1b)
2(ypT2N0)
1(ypT2N1a)
1(ypT2N0);1(ypT3N0)
1(ypT2N1a) 1(ypT3N2b)
T4N0
n = 1 1(ypT0N0)
cT3N2
n = 22
7(ypT0N0);
1(ypT0N1b)
3(ypT1N0);3(ypT2N0)
1(ypT2N1a);2(ypT2N1b)
1(ypT2N2a)1(ypT3N2a)
1(ypT1N0);1(ypT3N0)
1(ypT3N1a)
cT4N1-2
n = 1 1(ypT0N0)
cT3N0M1
n = 1 1(ypT0N0cM0)*
cT3N1M1
n = 2
1(ypT0N0M1)
1(ypT0N1aM1)
cT3N2M1
n = 3
1(ypT0N0M0)
1(ypT0N2bM0) 1(ypT2N2aM1)
cT4N2M1
n = 1 1(ypT0N0M1)
cTNM = clinical staging; ypTNM = pathological staging after chemoradiotherapy treatment
*clinical complete response of the lung metastases
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Although comparisons across studies should 
be made with caution, our findings are encouraging 
when compared to results of similar studies employing 
preoperative treatment on MRI-defined high-risk 
LARC patients [15]. Only two studies investigating the 
integration of bevacizumab into preoperative treatment 
reported a pCR rate >30% (Table 6 [16–28]).
Crane and colleagues [18] reported a pCR rate 
of 32% and an additional microscopic residual disease 
rate of 24% with the administration of capecitabine and 
Figure 1: Kaplan-Meier survival curves. Dashed curves represent 95% CIs. A. Progression-free survival for the schedule B.  
B. Overall survival for the schedule B.
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bevacizumab concomitant to preoperative RT. However, 
patient selection in this study, as with most studies 
assessing bevacizumab, was not based on MRI criteria 
(Table 6 [16–28]). Furthermore, PFS (with a shorter 
follow-up) was markedly lower than in our series [18]. A 
slightly higher pCR rate of 34% and an additional near-
ypCR rate of 36% were observed in a phase-2 study, in 
which patients received induction chemotherapy with 4 
cycles of bevacizumab plus XELOX, followed by CRT 
with concurrent capecitabine and bevacizumab. In this 
study, MRI selection criteria were used but, unlike in our 
study, patients with metastatic disease were not included, 
dose of RT was higher and long-term outcome was not 
reported [19].
With respect to safety, the combination of 
bevacizumab with RT and OXATOM/FUFA was well 
tolerated. Toxicities were manageable and similar to those 
previously reported with the same CRT regimen without 
bevacizumab [3]. Neutropenia was the most common 
toxicity but did not decrease the treatment compliance. 
Interestingly the incidence of grade ≥3 neutropenia 
reported for schedule B was lower compared to the 
same CRT regimen without or with bevacizumab in the 
concomitant schedule. In line with these results, recent 
preclinical data shows that the sequential delivery of 
antiangiogenic drugs followed by chemotherapy yields a 
lower bone marrow toxicity compared to the concomitant 
administration [29].
In agreement with some trials evaluating the 
integration of bevacizumab in preoperative treatment 
(Table 5), we observed high a rate of surgical 
complications and re-operation under schedule A, while 
postoperative complications in schedule B were relatively 
low (Table 5). We hypothesize that the administration of 
only two cycles of bevacizumab, and the resulting longer 
interval between its last administration and surgery, 
may have helped to reduce the occurrence of surgical 
complications. However, compared to the 2% rate of 
re-operation reported in larger phase III trial in patients 
treated with preoperative fluoropyrimidine alone during 
RT [30], the 9% rate observed with the sequential schedule 
is higher. Nevertheless, this rate is similar to that reported 
with other intensified treatment approaches, including our 
previous experience without bevacizumab [3, 31]. Notably 
when an intensified approach was used in combination 
with bevacizumab as preoperative treatment, an even 
higher re-operation rate was reported [19].
Our study has some potential limitations that deserve 
special consideration. Its major weakness is that it was a 
single center, non-randomized phase-2 trial, with a relatively 
small sample size. Furthermore, evidence is emerging that a 
margin of ≤1 mm from the MRF by MRI may be adequate 
Table 4: Treatment Related Toxicity
Schedule A (n = 16) Schedule B (n = 46)
Toxicity Grade 1–2 Grade 3–4 Total Grade 1–2 Grade 3–4 Total
No. % No. % No. % No. % No. % No. %
Neutropenia 7 44 7 44 14 87 9 20 14 30 23 50
Thrombocytopenia 1 6 0 1 6 1 2 1 2 2 4
Anemia 0 1 6 1 6 6 13 1 2 7 15
Nausea/vomiting 7 44 0 7 44 22 48 0 22 48
Abdominal pain 3 19 0 3 19 4 9 0 4 9
Diarrhea 6 37 1 6 7 43 16 35 3 6 19 41
Stomatitis 1 6 0 1 6 2 4 0 2 4
Proctitis 4 25 0 4 25 14 30 0 14 30
Proteinuria 3 19 0 3 19 4 9 0 4 9
Liver enzymes 2 12 0 2 12 9 20 1 2 10 22
Skin reactions 3 19 0 3 19 5 11 0 5 11
Asthenia 4 25 0 4 25 10 22 2 4 12 26
Neuropathy 2 12 0 2 12 6 13 0 6 13
Hypertension 4 25 1 6 5 31 11 24 0 11 24
Anorexia 2 12 0 2 12 3 6 2 4 5 10
Rectal tenesmus 2 12 0 2 12 6 13 0 6 13
Cystitis 2 12 0 2 12 4 9 0 4 9
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to identify patients at risk of CRM involvement [32], as 
opposed to the 5 mm threshold previously accepted [33]. 
A recent multicenter study showed that a cut-off of 2 mm 
from the MRF may help select patients in whom an intensive 
preoperative treatment is needed [34]. In our study, the tumor 
was located within 2 mm of MRF in 83% of patients and 
most patients had additional high-risk factors. Moreover, 
93% of patients showed clinical lymph node involvement 
and 15% had metastatic disease. Therefore, it seems unlikely 
that our results were influenced by favorable patient selection.
In conclusion, taking into account the few doses 
of bevacizumab associated with preoperative CRT, 
its scheduling seems to be crucial to potentiate the 
combination. We may hypothesize that, in this setting, 
bevacizumab might improve the delivery of cytotoxic 
drugs and oxygen to cancer cells through a reduction 
of the interstitial fluid pressure (“vessel normalization 
effect”), that has been proven to occur few days after a 
single drug administration [5], rather than through the 
reduction of vessel density (“tumor-starving effect”). 
If so, the sequential administration of bevacizumab and 
CRT, as opposed to concurrent, exploits this synergism at 
best. Of course, further studies are needed to validate this 
approach and better understand its underlying molecular 
mechanisms. Therefore, we are currently conducting 
a phase-3 randomized study comparing the two 
bevacizumab schedules in combination with FOLFOX/
OXXEL regimens in metastatic colorectal cancer patients 
(OBELICS study, NCT01718873).
MATERIALS AND METHODS
The BRANCH (Bevacizumab, RAdiotherapy 
aNd CHemotherapy) trial was an open label, non-
randomized, single center, phase-2 clinical study (Eudract 
number: 2008-003989-26; Clinicaltrials.gov number: 
NCT01481545), approved by the local ethical committee 
and conducted in accordance to the Declaration of 
Helsinki. Signed written informed consent was obtained 
from each patient before accrual.
Table 5: Postoperative Complications and late toxicities
Schedule A (n = 16) Schedule B (n = 46)
Patients with at least one complication, n (%) 8 (53%) 13 (28%)
Anastomotic fistula 3 3
Rectovaginal fistula 1 −
Pelvic infection 2 5
Anastomotic leak 1 2
Intestinal ischemia 1 −
Wound healing complication − 1
Urinary retention − 3
Rectal bleeding − 1
Stoma complication − 1
Anastomotic stenosis − 2
Patients with at least one late toxicity, n (%) 6 (40%) 19 (41%)
Sexual dysfunction
Erectile dysfunction 2 4
Retrograde ejaculation − 1
Dyspareunia 1 1
Anorectal dysfunction −
Fecal and gas incontinence 2 7
Higher stool frequency 2 5
Constipation − 1
Urinary dysfunction 1
Neurogenic bladder − 1
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Table 6: Main published phase II studies using bevacizumab in combination with preoperative 
radiochemotherapy
Author Reference Treatment schedule Eligible 
patients
Main 
Toxicity 
G3/G4 (%)
Postop erative 
compli cations* 
(%)
Complete 
tumor 
regression** 
(%)
Survival
Willett 
et al. [14, 15]
RT 50.4 Gy; BEV 
days−14, 1, 15, 29;
5FU 225 mg/m2/d days 
1–38
T3–T4
(n = 32) Diarrhea 22
Minor 28
Major 6 5/32 (16)
5-years 
DFS 77%
5-years 
OS 100%
Crane 
et al. [16]
RT 50.4 Gy; BEV days 1, 
15, 29;
Cap 900 mg/m2 b.i.d. days 
1–38
T3–T4 
and/or N+
(n = 25)
0 Minor 20Major 12 8/25 (32)
2-years 
DFS 69%
2-years 
OS 95%
Noguè 
et al. [17]
Induction: BEV+XELOX 
× 4;
RT 50.4 Gy; BEV days 1, 
15, 29;
Cap 825 mg/m2 b.i.d. days 
1–38
MRI- 
defined 
high-risk 
T3–T4 
and/or N+
(n = 47)
Diarrhea 11
Neutropenia 
6
Minor 34
Major 24 16/47 (34) NS
Velenik 
et al. [18]
RT 50.4 Gy; BEV 
days−14, 1, 15, 29;
Cap 825 mg/m2 b.i.d. days 
1–38
T3–T4 
and/or N+
(n = 61)
Dermatitis 
10
Minor 52
Major 10 8/61 (13) NS
Dipetrillo 
et al. [19]
Induction: BEV+FOLFOX 
× 2; RT 50.4 Gy; 
 BEV days 1, 15, 29; 
5FU200 mg/m2/d days 
1–38; 
 OX 40 mg/m2 weekly × 6 
weeks
T3–T4 
and/or N+
(n = 26)
Diarrhea 44
Neutro penia 
20
Minor 36 5/26 (19)
3-years 
DFS 65%
3-years 
OS 95%
Gasparini 
et al. [20]
RT 50.4 Gy; BEV 
days−14, 1, 15, 29;
Cap 825 mg/m2 b.i.d. days 
1–38
T3–T4 
and/or N+
(n = 43)
Diarrhea 7
Minor 7
Major 2° 6/43 (14)
3-years 
DFS 75%
Kennecke 
et al. [21]
RT 50.4 Gy; BEV 
days−14, 1, 15, 29;
Cap 825 mg/m2 b.i.d. days 
1–14 and 22–35; 
 OX 50 mg/m2 days 1, 8, 
22, and 29
High-risk 
T3–T4 
and/or N+
or 
anyTNM1
(n = 42)
Diarrhea 24
Rectal pain 
10
Minor 53
Major 10 9/42 (21) NS
Spigel 
et al. [22]
RT 50.4 Gy; BEV days 1, 
15;
5FU 225 mg/m2/d days 
1–42
T3–T4 
and/or N+
(n = 35)
Thrombo-
cytopenia 9
Diarrhea 6
Minor 3
Major 3
10/35 (29)
1-years 
DFS 85%
Landry 
et al. [23]
RT 50.4 Gy; BEV days 1, 
15, 29;
Cap 825 mg/m2 b.i.d. days 
1–38;
OX 50 mg/m2 weekly × 5 
weeks
T3–T4
(n = 54)
Rectal pain 
17
Diarrhea 
13§§
Minor 49
Major 6 9/54 (17) NS
(Continued )
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Patient selection
The study enrolled patients with pathologically 
confirmed untreated high-risk rectal adenocarcinoma within 15 
cm from the anal margin. High-risk was defined a tumor with 
concomitant resectable metastases and/or any of the following 
MRI features: T4; anyTN1-2; T3N0 tumors located in the 
lower third of the rectum and/or whose radial margin was 
≤5 mm from MRF. Tumors with radial margin ≤5 mm from 
MRF, defined by MRI, were considered to have potentially 
positive CRM. Other main eligibility criteria were: age ≥18 
years; ECOG performance status ≤2; adequate bone marrow, 
renal, and liver function; absence of concurrent uncontrolled 
medical condition; no previous malignant disease.
Author Reference Treatment schedule Eligible 
patients
Main 
Toxicity 
G3/G4 (%)
Postop erative 
compli cations* 
(%)
Complete 
tumor 
regression** 
(%)
Survival
Dellas 
et al. [24]
RT 50.4 Gy; BEV days 1, 
15, 29;
Cap 825 mg/m2 b.i.d. days 
1–14 and 22–35; 
 OX 50 mg/m2 days 1, 8, 
22, and 29
T3–T4 
and/or 
N+ or 
any TNM 
1livrs
(n = 69)
Diarrhea 4 Minor 55 12/69 (17) NS
Blasz-
kowsky 
et al.
[25]
RT 50.4 Gy; BEV days 
–14, 1, 15, 29;
5FU 225 mg/m2/d days 
1–38;
erlo 100 mg/m2/d days 
1–38
T3–T4
(n = 26)
Lympho-
penia 46
Diarrhea 19
Minor 65 7/26 (27) 3-years 
DFS 75%
Borg 
et al. [26]
Induction: BEV+FOLFOX 
× 6;
RT 45 Gy; BEV days−14, 
1, 15, 29;
5FU 225 mg/m2/d × 5 
days/week
MRI-
defined 
locally 
advanced 
T3
(n = 46)
Neutropenia 
20
Diarrhea 6
Gastroin-
testinal 
perforation 
4
Minor 22 10/46 (22) NS
Borg 
et al. [26]
RT 45 Gy; BEV days−14, 
1, 15, 29;
5FU 225 mg/m2/d × 5 
days/week
MRI-
defined 
locally 
advanced 
T3
(n = 45)
Diarrhea 6
Proctitis 4 Minor 22 5/45 (11) NS
Present 
study
Schedule 
B
RT 45 Gy; BEV days−4, 
11;
OX 100 mg/m2 + Tom 2.5 
mg/m2 days 1, 15 and 29; 
5FU 800 mg/m2 + LFA 250 
mg/m2 days 2, 16 and 30
MRI- 
defined 
high-risk 
T3–T4 
and/or 
N+ or any 
TNM1rs
(n = 46)
Neutropenia 
30
Diarrea 6
Minor 19
Major 9 23/46 (50)
5-years 
PFS 80%
5-years 
OS 85%
RT = radiotherapy; BEV = bevacizumab; 5-FU = 5-fluorouracil; Cap = capecitabine; OX = oxaliplatin; LFA = folinic acid; 
erlo = erlotinib; d = day; .livrs = single resectable liver metastasis; rs = resectable; MRI = magnetic resonance imaging; NS 
= not specified. DFS = disease free survival; PFS = progression free survival; OS = overall survival
*Postoperative surgery-related complications 
Major/minor requiring/not requiring surgical reintervention or drainage
**Various tumor regression grading systems used
°One postoperative death
§Two (4%) toxicity-related deaths (one sudden death and one ketoacidosis)
§§One toxicity-related death (aspiration)
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Baseline work-up was completed within 6 
weeks before the registration and included: clinical 
examination, laboratory tests, recto-colonoscopy and 
endorectal ultrasound; carcinoembryonic antigen (CEA) 
serum level; whole body contrast enhanced computed 
tomography (CT); MRI of the pelvis. Imaging studies 
were blindly reviewed by two radiologists (AP and VG) 
and in case of discrepancy the worse TNM was assigned.
Biomarker studies on tumor and blood samples 
and [18F]-2-fluoro-2-deoxy-D-glucose positron emission 
tomography (18FDG-PET) evaluation were also performed 
at baseline, during treatment and before surgery. Results of 
these studies will be described in separate reports.
Study Procedures
Treatment plan
The total dose of RT was 45 Gy delivered in 25 
fractions of 1.8 Gy, 5 days/week. The clinical target 
volume (CTV) included the tumor, with margins of 
2–3 cm depending on tumor direction, mesorectum and 
regional lymph nodes. The planning target volume was 
defined as CTV + 1 cm margin.
Chemotherapy given during RT consisted of 
three biweekly cycles of infusional oxaliplatin, 100 
mg/m2 followed by raltitrexed, 2.5 mg/m2 on day 1, 
and levo-folinic acid, 250 mg/m2 followed by bolus of 
5-fluorouracil, 800 mg/m2 on day 2.
Bevacizumab 5 mg/kg was administered 2 
weeks before the start of CRT, and on the same day of 
oxaliplatin and raltitrexed for 3 cycles (treatment days: 
-14, 1, 15 and 29; concomitant schedule A) or 4 days 
prior to the first and second cycle of chemotherapy 
(treatment days: -4, and 11; sequential schedule B) 
(Figure 2). Two additional cycles of chemotherapy 
with one bevacizumab infusion, using the previously 
employed timing schedule, were allowed after the end of 
CRT in patients with metastatic disease.
CRT had to be temporarily stopped in case of 
grade ≥3 toxicity. Dose adjustments for adverse events 
were reported previously [35]. Total mesorectal excision 
(TME) was planned 8 weeks (±1) after the last day 
of RT. The choice of surgical procedure for primary 
tumor, anterior or abdominal–peritoneal resection, and 
metastases was based on restaging. Fecal diversion 
to protect the anastomosis was performed by means 
of a loop ileostomy, which was later reversed after 
endoscopic assessment of anastomotic integrity. All 
patients underwent clinical tumor response assessment 
before surgery with the same imaging modalities that 
were used for the inclusion into the study.
Figure 2: Treatment schedules. 
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Pathology
Tumor regression grade (TRG) was blindly 
measured according to the Mandard scale [36] by two 
pathologists (GB and FT). In case of discrepancy between 
the two the worse TRG score was assigned.
A complete pathologic response (ypCR,) was 
defined as the absence of viable tumor cells in the primary 
tumor and lymph nodes (ypT0N0). Radical resection (R0) 
was defined as macroscopic and microscopic tumor-free 
resection for both primary tumor (CRM > 1 mm) and 
metastatic disease (margins > 1 mm from tumor).
Adjuvant treatment and follow up
Four months of post-operative FOLFOX4 regimen, 
no earlier than 4 weeks after surgery, was planned only 
in patients with ypN+ or CRM ≤ 1 mm at pathology 
examination, or for those with baseline metastatic disease 
eventually resected with an R0/R1 status.
Clinical examination, CEA serum level, whole body 
CT and pelvic MRI, were performed every 4 months for 
the first 2 years of follow up, every 6 months for the next 
3 years, and annually thereafter.
Statistical design and analysis
The primary end point of this study was the rate of 
TRG1. To establish the sample size, the Simon’s two-stage 
design was applied [37]. Setting α and β errors at 0.05 and 
0.20, respectively, and defining as the minimum activity 
of interest (p0) a TRG1 rate of 30%, in order to accept 
the alternative hypothesis (p1) of a TRG1 rate ≥ 50%, at 
least 6 TRG1 in the first 15 patients and at least 19 TRG1 
among a total of 46 patients would need to be reported in 
the first and second stage, respectively.
The study protocol provided that the sequential 
schedule of bevacizumab would be evaluated only if 
the required number of TRG1 was not reached with the 
concomitant schedule. Other endpoints included toxicity, 
surgical morbidity, and long-term outcome.
Toxicities, were graded according to the National 
Cancer Institute common toxicity criteria (NCI CTC-
Version 3). Postoperative complications were included in 
this report when occurring within 90 days from surgery. 
Late toxicity was assessed using the SOMA-LENT scale 
[38]. Proportions were calculated with their exact 95% 
confidence interval (CI).
PFS was calculated from the date of initial treatment 
until tumor progression or relapse, death for any cause or 
last follow-up. OS was calculated from the date of initial 
treatment to the date of death for any cause or last follow-
up. PFS and OS rates were estimated with their 95% CI 
using the Kaplan-Meier method. Analysis was based on the 
intention-to-treat, and was performed using SPSS statistical 
analysis software (version 12.0; SPSS Inc.). No comparison 
between the two cohorts of patients was planned. The end 
point database was updated in December 2014.
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